Loading...

CTI BioPharma

DB:CEPS
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CEPS
DB
$58M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The last earnings update was 43 days ago. More info.


Add to Portfolio Compare Print
  • CTI BioPharma has significant price volatility in the past 3 months.
CEPS Share Price and Events
7 Day Returns
0%
DB:CEPS
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-
DB:CEPS
-5.6%
DE Biotechs
-4.5%
DE Market
CEPS Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
CTI BioPharma (CEPS) 0% 7.9% -3.7% - -80.9% -96%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • No trading data on CEPS.
  • No trading data on CEPS.
Price Volatility
CEPS
Industry
5yr Volatility vs Market
Related Companies

CEPS Value

 Is CTI BioPharma undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for CTI BioPharma. This is due to cash flow or dividend data being unavailable. The share price is €0.903.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for CTI BioPharma's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are CTI BioPharma's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CEPS PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.52
NasdaqCM:CTIC Share Price ** NasdaqCM (2019-04-25) in USD $0.99
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of CTI BioPharma.

DB:CEPS PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CTIC Share Price ÷ EPS (both in USD)

= 0.99 ÷ -0.52

-1.88x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CTI BioPharma is loss making, we can't compare its value to the Europe Biotechs industry average.
  • CTI BioPharma is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does CTI BioPharma's expected growth come at a high price?
Raw Data
DB:CEPS PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.88x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-32.5%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for CTI BioPharma, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on CTI BioPharma's assets?
Raw Data
DB:CEPS PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.01
NasdaqCM:CTIC Share Price * NasdaqCM (2019-04-25) in USD $0.99
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:CEPS PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CTIC Share Price ÷ Book Value per Share (both in USD)

= 0.99 ÷ 1.01

0.97x

* Primary Listing of CTI BioPharma.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • CTI BioPharma is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess CTI BioPharma's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. CTI BioPharma has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

CEPS Future Performance

 How is CTI BioPharma expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-32.5%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is CTI BioPharma expected to grow at an attractive rate?
  • Unable to compare CTI BioPharma's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare CTI BioPharma's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • CTI BioPharma's revenues are expected to decrease over the next 1-3 years, this is below the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CEPS Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CEPS Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -32.5%
DB:CEPS Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts -149.8%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CEPS Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CEPS Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 0 -60 2
2019-12-31 0 -52 2
DB:CEPS Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 26 -40 -29
2018-09-30 12 -38 -45
2018-06-30 13 -46 -42
2018-03-31 35 -33 -29
2017-12-31 25 -39 -45
2017-09-30 34 -43 -37
2017-06-30 37 -36 -54
2017-03-31 22 -62 -75
2016-12-31 57 -77 -52
2016-09-30 60 -84 -74
2016-06-30 56 -95 -78
2016-03-31 50 -94 -91

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • CTI BioPharma is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • CTI BioPharma's revenue is expected to decrease over the next 1-3 years, this is not considered high growth.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CEPS Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from CTI BioPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CEPS Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31 -1.03 -0.95 -1.11 2.00
2019-12-31 -0.89 -0.81 -0.97 2.00
DB:CEPS Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.52
2018-09-30 -0.85
2018-06-30 -0.86
2018-03-31 -0.70
2017-12-31 -1.24
2017-09-30 -1.13
2017-06-30 -1.88
2017-03-31 -2.68
2016-12-31 -1.86
2016-09-30 -2.80
2016-06-30 -3.24
2016-03-31 -4.23

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if CTI BioPharma will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess CTI BioPharma's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
CTI BioPharma has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

CEPS Past Performance

  How has CTI BioPharma performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare CTI BioPharma's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • CTI BioPharma does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare CTI BioPharma's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare CTI BioPharma's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
CTI BioPharma's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from CTI BioPharma Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CEPS Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 26.29 -29.40 21.18 36.47
2018-09-30 12.28 -44.51 20.31 34.04
2018-06-30 13.26 -41.68 22.46 31.91
2018-03-31 34.87 -29.29 25.56 31.70
2017-12-31 25.15 -45.02 31.44 32.87
2017-09-30 33.82 -37.13 35.66 33.47
2017-06-30 36.55 -54.34 45.07 43.59
2017-03-31 21.68 -75.15 46.68 51.37
2016-12-31 57.41 -52.01 47.31 62.96
2016-09-30 59.59 -74.47 53.46 74.69
2016-06-30 56.12 -77.88 51.92 75.38
2016-03-31 49.86 -90.71 54.98 78.00
2015-12-31 16.12 -122.62 55.96 74.63
2015-09-30 22.58 -137.98 53.74 75.07
2015-06-30 61.15 -100.78 52.62 73.19
2015-03-31 61.39 -95.59 53.79 67.89
2014-12-31 60.08 -95.99 58.24 62.60
2014-09-30 75.17 -41.60 57.62 50.73
2014-06-30 36.00 -68.65 53.59 41.45
2014-03-31 34.96 -59.26 49.90 35.45
2013-12-31 34.68 -49.64 44.44 31.62
2013-09-30 1.79 -78.87 38.99 32.74
2013-06-30 1.43 -76.63 38.23 32.45
2013-03-31 1.13 -117.21 39.46 33.39
2012-12-31 -115.28 40.94 30.50
2012-09-30 -114.11 42.02 37.00
2012-06-30 -123.60 42.01 37.58

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if CTI BioPharma has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if CTI BioPharma has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if CTI BioPharma improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess CTI BioPharma's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
CTI BioPharma has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

CEPS Health

 How is CTI BioPharma's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up CTI BioPharma's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • CTI BioPharma is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • CTI BioPharma's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of CTI BioPharma's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.9x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from CTI BioPharma Company Filings, last reported 3 months ago.

DB:CEPS Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 52.94 14.08 67.04
2018-09-30 51.36 14.39 80.92
2018-06-30 63.65 14.26 92.82
2018-03-31 77.05 14.14 104.63
2017-12-31 16.09 14.02 27.22
2017-09-30 28.41 14.79 52.80
2017-06-30 38.92 15.43 74.74
2017-03-31 -10.37 17.36 33.30
2016-12-31 7.76 19.26 44.02
2016-09-30 12.52 21.10 61.61
2016-06-30 36.76 22.87 76.71
2016-03-31 54.74 24.60 104.64
2015-12-31 47.41 56.50 128.20
2015-09-30 -27.52 51.65 46.36
2015-06-30 -15.53 51.62 54.86
2015-03-31 14.12 15.24 44.40
2014-12-31 38.48 17.38 70.93
2014-09-30 16.05 13.71 29.91
2014-06-30 6.68 13.55 33.18
2014-03-31 23.23 13.39 50.60
2013-12-31 42.76 13.31 71.64
2013-09-30 0.39 8.34 27.18
2013-06-30 -0.36 8.20 28.57
2013-03-31 16.10 8.07 44.31
2012-12-31 32.94 0.00 50.44
2012-09-30 -9.90 0.00 14.29
2012-06-30 -14.95 0.00 14.76
  • CTI BioPharma's level of debt (26.6%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (31.3% vs 26.6% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • CTI BioPharma has sufficient cash runway for 1.7 years based on current free cash flow.
  • CTI BioPharma has sufficient cash runway for 2.1 years if free cash flow continues to reduce at historical rates of -38.6% each year.
X
Financial health checks
We assess CTI BioPharma's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. CTI BioPharma has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

CEPS Dividends

 What is CTI BioPharma's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from CTI BioPharma dividends.
If you bought €2,000 of CTI BioPharma shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate CTI BioPharma's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate CTI BioPharma's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CEPS Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CEPS Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as CTI BioPharma has not reported any payouts.
  • Unable to verify if CTI BioPharma's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of CTI BioPharma's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as CTI BioPharma has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess CTI BioPharma's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can CTI BioPharma afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. CTI BioPharma has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

CEPS Management

 What is the CEO of CTI BioPharma's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Adam Craig
COMPENSATION $5,692,447
AGE 52
TENURE AS CEO 2.1 years
CEO Bio

Dr. Adam R. Craig, M.D., Ph.D., M.B.A., has been the Chief Executive Officer, President and Director of CTI BioPharma Corp. since March 20, 2017 and serves its Interim Chief Medical Officer. Dr. Craig served as Independent Consultant at CTI BioPharma Corp. since 2016 until March 20, 2017. Dr. Craig served as an Interim Chief Medical Officer at Immune Design Corp. since June 2016 until April 26, 2017. He has over 20 years of experience in hematology, oncology and drug development in both the US and Europe. He served as the Chief Medical Officer and Executive Vice President of Development at Sunesis Pharmaceuticals Inc. from March 1, 2012 to 2016. He oversaw the ongoing pivotal Phase 3 VALOR trial of vosaroxin in patients with first relapsed or refractory acute myeloid leukemia (AML) and direct Sunesis’ global development program. He served as the Chief Medical Officer and Senior Vice President of Chemgenex Pharmaceuticals Ltd. from 2008 to 2012. He served as the Chief Medical Officer and Vice President of CytRx Oncology Corporation (formerly Innovive Pharmaceuticals, Inc.) from April 2005 to September 30, 2007. From December 17, 2003 to April 2005, he served as Vice President of Clinical Development and Medical Director of ArQule Inc. Dr. Craig joined ArQule from Ilex Oncology, Inc., where he was Senior Director of Clinical Development and Medical Director from April 2002 to December 2003. Prior to Ilex, Dr. Craig served as Medical Adviser in oncology at Antisoma, from March 2001 to March 2002. He served as a Product Development Reviewer for the Cancer Prevention Research Institute of Texas. Dr. Craig was a Medical Research Council Clinical Research Fellow from January 1998 to February 2001. Dr. Craig is a Member of the Royal College of Physicians (UK) and undertook Post-Graduate Training in Pediatrics and Pediatric Oncology. Dr. Craig earned his Bachelor’s and Medical degrees from University of London’s Charing Cross and Westminster Medical School in July 1999 and holds a Ph.D. in Molecular Oncology from Leeds University in the U.K. in June 2001 and an MBA from the Open Business School, in the United Kingdom.

CEO Compensation
  • Insufficient data for Adam to compare compensation growth.
  • Adam's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the CTI BioPharma management team in years:

1.8
Average Tenure
64
Average Age
  • The average tenure for the CTI BioPharma management team is less than 2 years, this suggests a new team.
Management Team

Adam Craig

TITLE
President
COMPENSATION
$6M
AGE
52
TENURE
2.1 yrs

Jack Singer

TITLE
Co-Founder & Consultant
COMPENSATION
$2M
AGE
75

David Kirske

TITLE
Executive VP
COMPENSATION
$1M
AGE
64
TENURE
1.6 yrs

Bruce Seeley

TITLE
Executive VP & COO
COMPENSATION
$1M
AGE
54
TENURE
1.6 yrs

Ed Bell

TITLE
Senior Director of Investor Relations
TENURE
10.8 yrs

Jim Fong

TITLE
Senior Vice President of US Commercial Operations

Bruce Bennett

TITLE
Senior Vice President Global Pharmaceutical Operations
AGE
66
Board of Directors Tenure

Average tenure and age of the CTI BioPharma board of directors in years:

2.3
Average Tenure
54
Average Age
  • The average tenure for the CTI BioPharma board of directors is less than 3 years, this suggests a new board.
Board of Directors

Laurent Fischer

TITLE
Chairman of the Board
COMPENSATION
$148K
AGE
54
TENURE
1.6 yrs

Adam Craig

TITLE
President
COMPENSATION
$6M
AGE
52
TENURE
2.1 yrs

Reed Tuckson

TITLE
Director
COMPENSATION
$238K
AGE
67
TENURE
7.6 yrs

Dan Von Hoff

TITLE
Chairman of Scientific Advisory Board
AGE
70
TENURE
5.8 yrs

Michael Metzger

TITLE
Director
COMPENSATION
$333K
AGE
47
TENURE
2.3 yrs

David Parkinson

TITLE
Director
COMPENSATION
$176K
AGE
68
TENURE
1.8 yrs

Matthew Perry

TITLE
Director
COMPENSATION
$238K
AGE
45
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess CTI BioPharma's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. CTI BioPharma has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

CEPS News

Simply Wall St News

CEPS Company Info

Description

CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. It develops PIXUVRI, a novel aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma; and pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; University of Vermont; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.

Details
Name: CTI BioPharma Corp.
CEPS
Exchange: DB
Founded: 1991
$51,833,997
57,966,325
Website: http://www.ctibiopharma.com
Address: CTI BioPharma Corp.
3101 Western Avenue,
Suite 800,
Seattle,
Washington, 98121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CTIC Common Stock Nasdaq Capital Market US USD 21. Mar 1997
DB CEPS Common Stock Deutsche Boerse AG DE EUR 21. Mar 1997
LSE 0RLB Common Stock London Stock Exchange GB EUR 21. Mar 1997
DB CEPS COM NPV(POST REV SPLIT) Deutsche Boerse AG DE EUR 25. Apr 2019
Number of employees
Current staff
Staff numbers
46
CTI BioPharma employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 21:31
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/14
Last earnings filing: 2019/03/13
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.